Reimagining Oncology Clinical Trials with Digital Biomarkers

Overview:

Health metrics enabled by wearables are a huge untapped opportunity in oncology clinical trials. Especially in chronic cancer such as leukemias, quantitative evidence that a therapeutic improves activity levels, sleep, and other quality of life measures can drive value differentiation and sales growth. Yet, sponsors of cancer clinical trials have been slower to embrace digital outcome measures than their peers in other therapeutic areas.

In this paper, we look at the perceived barriers to the adoption of wearables—and the major benefits that await sponsors that overcome them.

Key Takeaways:

• Opportunities for improving oncology drug studies with wearables
• Common perceived barriers to wearables adoption debunked by clinical evidence
• Quality of life factors and how they can drive product differentiation